Small biotechs with big drug am­bi­tions threat­en to up­end the tra­di­tion­al drug launch play­book

Of the count­less de­ci­sions Vlad Coric had to make as Bio­haven’s CEO over the past sev­en years, there was one that felt par­tic­u­lar­ly nerve-wrack­ing: In­stead of sell­ing to a Big Phar­ma, the com­pa­ny de­cid­ed it would com­mer­cial­ize its mi­graine drug it­self.

“I re­mem­ber some in­vestors yelling and pound­ing on the ta­ble like, you can’t do this. What are you think­ing? You’re go­ing to get crushed by Ab­b­Vie,” he re­called.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER